Form 4 for REVB REVELATION BIOSCIENCES, INC.
Accepted 2026-01-12 00:00:00 ET · period of report 2026-01-08 · accession 0001193125-26-010648 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-12 | 2026-01-08 | REVB | Rolke James | CEO, Dir | A - Grant | $0.9 | +532.8K | 933.5K | +133% | +$479.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-08 | A | A | 532,829 | $0.9 | 933,489 | D | — | — | (F1) Restricted Stock Units under the 2021 Equity Incentive Plan. Vests quarterly over two years from the date of grant. |